AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06215690 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound measurements
Description: Evaluation will be performed by ultrasonography. The following measurements will be taken with the ultrasonographic examination.~* BPD (Biparietal Diameter)~* HC (Head Circumference)~* AC (Abdominal Circumference)~* FL (Femur Length)~* EFW (Estimated Fetal Weight)~* Umbilical Artery Doppler Sistole/Diastole (S/D) ,Pulsatility İndex (PI), Resistance İndex (RI)~* Middle Cerebral Artery S/D,PI,RI~* Uterine Artery Doppler PI~* Anterior Cerebral Artery S/D,PI,RI~* CPUR (Cerebral - Placental - Uterin PI Ratio)~* CPR (Cerebral - Placental PI Ratio)~* The deepest free single vertical pocket in the amnion mai~* Cavum Septum Pellucidum: Width - Length Diameters~* OFD (Occipitofrontal length)~* FAPD (Frontal Anterior Posterior Diameter)~* FAPD/OFD ratio~* Cerebellar diameter~* Lateral ventricle depth~* Insular depth~* Sylvian fissure depth
Study NCT04547166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX10
Description: a single fixed dose of 300 mg, intravenous infusion (IV), every 3 weeks (Day 1 of each cycle \[D1\]), non-reducible.
Study NCT04547166 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX04、
Description: 7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
Study NCT04547166 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HLX04、
Description: 7.5mg/kg, IV, every 3 weeks (D1 of each cycle), non-reducible.
Study NCT06544837 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Window of Implantation
Description: Determine the subject's window of implantation through testing and adjust the embryo implantation time
Study NCT05426720 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention; This study is a observational study. All patients received routine anti-tuberculosis regimen. Researchers will observe the clinical manifestation, pulmonary function and pulmonary CT manifestation within a few years after the cure of tuberculosis.
Study NCT05079009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ECCO2R pulsatile configuration
Description: Use of the pulsatile extracorporeal blood flow configuration.
Study NCT05017896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Normal CT Renal Perfusion imaging indexes
Description: A CT imaging which indicates the status of renal perfusion is normal.
Study NCT05017896 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Low CT Renal Perfusion imaging indexes
Description: A CT imaging which indicates the status of renal perfusion is low.
Study NCT04811274 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood collection
Description: 2 to 5 ml
Study NCT04811274 — intervention group
Intervention type: BIOLOGICAL
Intervention: Bronchoalveolar lavage fluid collection
Description: 5 to 25 ml
Study NCT06585527 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TS-2021
Description: The participants meeting the criteria will undergo TS-2021 oncolytic virus (5×1011PFU/ml) intratumoral injection using stereotactic technique under MR Localization.
Study NCT06006247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CVN424 150 mg
Description: Participants will receive 1 CVN424 tablet (150 mg) per day.
Study NCT06006247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive 1 matching placebo tablet per day.
Study NCT05982301 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU
Description: The study has only one arm. Sintilimab 200mg d1 ivgtt+paclitaxel-albumin 125mg/m2 d1 ivgtt+oxaliplatin 85mg/m2 d1 ivgtt+5-FU 2.4g/m2 civ46h, q2w.
Study NCT05226858 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Transesophageal echocardiography (TEE)
Description: Sensitivity and specificity of TEE in identification of BTAI
Study NCT04687735 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intervention after nerve block
Description: Brachial plexus block + Physical therapy
Study NCT05043688 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: The study perform preoperative neoadjuvant therapy, surgery and postoperative adjuvant therapy on subjects. Preoperative neoadjuvant therapy includes 3 groups: iCamrelizumab combined with neoadjuvant chemotherapy; Camrelizumab combined with neoadjuvant radiochemotherapy, and neoadjuvant radiochemotherapy.
Study NCT05207930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GAmified HOme-based COgnitive-Nutrition training (GAHOCON)
Description: A home-based tablet game training, in which participants are expected to apply the nutrition knowledge they learn from the centre-based nutritional education and their cognitive functions.~Participants in the intervention group are expected to engage in the home-based training regularly during those 8 weeks. A team of registered social workers working in the elderly community centre will monitor the progress, remind, set goals, and provide supports to the participant remotely on WhatsApp.
Study NCT05207930 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Centre-based online open-source cognitive games
Description: During the 8 weeks in which the intervention group receives GAHOCON treatment, the control group will be introduced to some online open-source cognitive games (e.g. CogniFit) and are encouraged to play those games at the elderly community centre. However, the content of these games are unrelated to nutrition and the training is gamified to a less extent compared to GAHOCON. They will have free access to these online open-source cognitive games at the elderly community centre.
Study NCT05856955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Coaching Intervention
Description: The intervention uses a mHealth virtual tool that facilitates human-device interaction and is delivered by smartphone application. The program has coaching and education components that lead to chronic disease behavior change. It has been previously validated to improve self-management, medication adherence, and quality of life in individuals with CVD. The participant engages by selecting responses on the touch screen. In this manner, participants converse with the coach, develop a therapeutic alliance, and record responses. The investigators will institute behavior change methodology to enhance intervention efficacy.
Study NCT05856955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Smart phone without health coach. A basic health application is installed on the smart phone provided to the participant.
Study NCT06344026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ANPD001
Description: Biologic: ANPD001 is an experimental product derived from the patient's own skin cells converted to induced pluripotent stem cells. The stem cells were differentiated into precursors for brain cells that produce dopamine.
Study NCT03874845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Cognitive Therapy
Description: Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
Study NCT03874845 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle Relaxation Therapy
Description: Participants will attend 8 weekly group therapy sessions. Prior to and after therapy participants will have assessments related to their PTSD, fill out surveys, and have an fMRI.
Study NCT05960864 — intervention group
Intervention type: DRUG
Intervention: Celecoxib
Description: If we find any behavior that affects the safety of patients in the experiment, we will stop
Study NCT06344026 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Custom Device
Description: A custom device to facilitate slow injection of small volumes of investigational drugs (including cell therapies), under MRI guidance
Study NCT06150716 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ION356
Description: Administered as intrathecal (IT) injection.
Study NCT06058520 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota - lyophilized
Description: Patients receive 2 capsules daily for one week followed by one capsule daily for 2 weeks. MTT capsules are derived from a single donor per patient.
Study NCT06058520 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drug
Description: The placebo consists of a mixture of trehalose and crystalline methylcellulose (Avicel) in 6:1 (w/w) ratio that is packaged in size 0 swedish orange capsules, which are then double encapsulated in size 00 natural colored capsules to make them visibly indistinguishable from encapsulated active product.
Study NCT06169592 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Related transplantation of the right lobe of the liver
Study NCT04441320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Coated metal ureteral stent(CMUS)
Description: Coated metal ureteral stent aims to treat the patients with refractory ureteral stricture, such as radiation induced ureteral stricture. In this study, CMUS is indwelled to observe the efficacy and safety in the treatment of radiation induced ureteral stricture compared with Double-J stent.
Study NCT04441320 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Double-J stent(DJS)
Description: Double-J stent is commonly used for treatment of kinds of ureteral stricture. In this study, DJS is indwelled as a controlled group.
Study NCT06363110 — intervention group
Intervention type: DRUG
Intervention: Vericiguat (Verquvo, BAY1021189)
Description: Follow clinical practice/administration
Study NCT05147922 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Training with the Neonatal Resuscitation Quality Improvement Cart
Description: The cart will give providers audio-visual feedback and walk them through how to perform effective positive pressure ventilation with correct head positioning, appropriate Peak Inspiratory Pressure and Peak End Expiratory Pressure, no mask leak and ventilation rate of 40 per minute. Participants will be able to spend up to 30 minutes with the cart before undergoing their 1 minute assessment, which will be without feedback.
Study NCT05194761 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal saline
Description: Using normal saline nebulization in neonates postextubation
Study NCT04709432 — intervention group
Intervention type: PROCEDURE
Intervention: ECMO
Description: ECMO is a form of Extracorporeal Life Support (ECLS) to support either the pulmonary, or both the pulmonary and cardiac systems.
Study NCT06280144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza Vaccine, Live, Nasal, Freeze-dried
Description: The titer of live attenuated influenza virus containing A (H1N1) and A (H3N2) should not be less than 6.9 lg EID50, and the titer of live attenuated influenza B virus should not be less than 6.4 lg EID50
Study NCT05915962 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collecting a Nanofat-type microfat autograft
Description: Collecting and preparing a Nanofat autograft.~The protocol provides for the fat sample to be taken in a doctor's office during a consultation. The preparation will then be carried out at the MEARY center for cell and gene therapy of the AP-HP, at the Saint Louis hospital in Paris.
Study NCT05470504 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegvisomant
Description: 30 mg subcutaneously every day for 4 weeks.
Study NCT06280144 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile water for inhalation
Description: Sterile water for inhalation
Study NCT05316155 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib Intravesical Delivery System
Description: Erdafitinib intravesical delivery system will be administered.
Study NCT05639816 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline irrigation group
Description: Normal saline irrigation of common bile duct after complete stone removal
Study NCT05776641 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GENUS
Description: Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
Study NCT05776641 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: GENUS
Description: Participants will use the GENUS light and sound device at home for 60 minutes daily for 12 months
Study NCT04806646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonidegib
Description: TS1: assumption 14 days on and 14 days off. TS2: assumption 7 days on and 21 days off.
Study NCT04754672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous aerobic and resistance exercise intervention
Description: Continuous aerobic and resistance exercises intervention
Study NCT04754672 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Continuous aerobic and aerobic interval exercise intervention
Description: Continuous aerobic and aerobic interval exercise intervention
Study NCT06430541 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: A tryptamine that produces its behavioral effects primarily by acting as post-synaptic agonists at serotonin 5-HT2A and 5-HT2c receptors.
Study NCT04185337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fine-Needle Aspiration
Description: Undergo ultrasound-guided FNA
Study NCT04185337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymph Node Biopsy
Description: Undergo ultrasound-guided lymph node biopsy
Study NCT04185337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Photoacoustic Imaging
Description: Undergo ultrasound-guided PAI
Study NCT04185337 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Undergo ultrasound
Study NCT04185337 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multispectral optoacoustic tomography (MSOT) acuity instrument
Description: Use multispectral optoacoustic tomography (MSOT) acuity instrument
Study NCT05504798 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selected physical therapy program
Description: Selected physical therapy program one hour three times weekly for six successive weeks including stretching, strengthening, balance, and gait training.
Study NCT05504798 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted serial casting
Description: Interrupted casting for 5 days a week for six successive weeks using a dual cast which consists of a standard short leg cast and a circular cast from below the knee to above the knee.
Study NCT05504798 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular electrical stimulation
Description: Neuromuscular electrical stimulation in form of faradic current with frequency of 50 Hz, and intensity of maximum tolerable intensity to produce a visible contraction but as tolerated by the child for ankle dorsiflexors and knee extensors muscles through cast windows over the motor points of these muscles for 30 min 3 times weekly for six successive weeks
Study NCT05018403 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravenous AON-D21
Description: AON-D21 is a Pegylated L-configured aptamer that binds and thereby neutralizes the complement component C5a from activating both C5a receptors.
Study NCT05018403 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous placebo
Description: Isotonic glucose solution identical in appearance to AON-D21.
Study NCT04191447 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flamboyant 200/12
Description: Flamboyant 200/12 capsule
Study NCT04191447 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide / Formoterol 400/12
Description: Budesonide / Formoterol 400/12 capsule
Study NCT04191447 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flamboyant 200/12 Placebo
Description: Flamboyant 200/12 Placebo capsule
Study NCT04191447 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Budesonide / Formoterol 400/12 Placebo
Description: Budesonide / Formoterol 400/12 Placebo capsule
Study NCT05263804 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
Description: No intervention. Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection
Study NCT05263804 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cardiac MRI with gadolinium injection - Ancillary Study
Description: Collection of blood samples and MRI imaging in order to create a bio- and imaging-collection. 100 patients are expected in this group, for each of them, specific cardiac MRI with gadolinium injection will be done at day 6. Moreover, those 100 patients will follow the same visit schedule as the patients in the cohort group.
Study NCT04540835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavity pretreatment (Teethmate Desensitizer, Kuraray)
Description: Calcium phosphate desensitizer applied after caries removal. After restored using an oblique incremental technique with a composite resin (Filtek Z250, 3M Espe, USA)
Study NCT06638606 — intervention group
Intervention type: BEHAVIORAL
Intervention: Sleep improvement techniques
Description: Insomniac and hypersomniac individuals are given behavioral counselling to improve sleep.
Study NCT05265273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nipocalimab
Description: Nipocalimab will be administered as an IV infusion.
Study NCT06492954 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Removal of all lung nodules, including the radiated nodule, per the standard of care for osteosarcoma patients with lung metastasis.
Study NCT06492954 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy (SBRT)
Description: Dose level 1: 8 Gy\* 3 (Total 24 Gy) Dose level 2: 18 Gy\* 3 (Total 54 Gy)
Study NCT06186479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aconite pain oil
Description: Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
Study NCT06186479 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants apply 6 ml oil topically 2 times per day (morning and evening) for 15 to 27 weeks on chemotherapy-free days as long as they receive chemotherapy.
Study NCT06492954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: For subjects \<18 years of age at the time of enrollment, Atezolizumab will be administered IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg (maximum dose of 1200 mg). Subjects ≥ 18 years old will receive a flat dose of 1200 mg IV on Day 1 of each 21-day cycle
Study NCT05567185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib Intravesical Delivery System
Description: Erdafitinib intravesical delivery system will be administered.
Study NCT06386874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q Therapeutic System (BQ 3.0) - Sham
Description: The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.
Study NCT06386874 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Q Therapeutic System (BQ 3.0) - Sham
Description: The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery. Frequency and intensity parameters will be set to zero so that no stimulation is delivered.
Study NCT06386874 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Q Therapeutic System (BQ 3.0) - Active
Description: The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
Study NCT06386874 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Q Therapeutic System (BQ 3.0) - Active
Description: The BQ 3.0 is a medical device that produces and delivers non-invasive, extremely low intensity and frequency (1-100 Hz.; 0.1-1.0 G), frequency tuned electromagnetic fields in order to stimulate neuronal networks with the aim of reducing disability and promoting neurorecovery
Study NCT06431438 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
Study NCT04837508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MRG002
Description: Administrated intravenously
Study NCT06431438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
Study NCT06431438 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: TQA3810
Description: TQA3810 is a small-molecule Toll-like receptor (TLR8) agonist
Study NCT06281418 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granisetron 1 Mg/mL Intravenous Solution
Description: 2mL intraperitoneal adminstration of granisetron (1 mg/mL)
Study NCT06281418 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2 ml IP normal saline (0.9% NaCl)